Is it possible to prevent atrophy of key brain regions related to cognitive decline and Alzheimer's disease (AD)? 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Is it possible to prevent atrophy of key brain regions related to cognitive decline and Alzheimer's disease (AD)? 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Scale of benefit is comparable with in-person training, indicating its potential as a public health intervention. 3 key findings →
Design: randomized controlled trial Participants: 2,912 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of 6 952 440 vaccinated patients in the derivation cohort, 5 150 310 (74.1%) had two vaccine doses. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment and intervention thresholds, management of vertebral fractures, non-pharmacological and pharmacological treatments, including duration and monitoring of anti-resorptive therapy, glucocorticoid-induced osteoporosis, as well as models of care for fracture prevention. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Data were drawn from the UK Biobank cohort study with a total of 228 223 participants with Hospital Episodes Statistics and primary care linkage health records. 4 key findings →
Design: cohort study Participants: 2,378 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's dementia affects more than 40 million people worldwide with substantial increases in prevalence anticipated. 1 key finding →
Design: cohort study Participants: 24,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
AS01-adjuvanted shingles (herpes zoster) vaccination is associated with a lower risk of dementia, but the underlying mechanisms are unclear. 3 key findings →
Design: cohort study Participants: 436,788 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Folic acid supplements may sometimes therefore include vitamin B12 supplements with simultaneous administration of vitamin B12.Lesser degrees of folate inadequacy are associated with high blood levels of the amino acid homocysteine which has been linked with the risk of arterial disease, dementia and Alzheimer's disease. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Varicella-zoster virus (VZV) is a neurotropic virus that establishes lifelong latency in humans. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study shows that Hcy levels could modify the association between red blood cell n-3 PUFA and executive function. 2 key findings →
Participants: 1,680 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Previous hypothesis-driven research has identified many risk factors linked to dementia. 4 key findings →
Participants: 344,324 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Interventions that have even quite modest effects at the individual level could drastically reduce the future burden of dementia associated with Alzheimer's disease at the population level. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Epilepsy has been associated with cognitive impairment and potentially dementia in older individuals. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Observational population studies indicate that prevention of dementia and cognitive decline is being accomplished, possibly as an unintended result of better vascular prevention and healthier lifestyles. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
At least 45% of dementia and 60% of stroke cases are due to modifiable risk factors and could in part be prevented through healthy behavior. 3 key findings →
Design: cross-sectional Participants: 1,478 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Identification of modifiable risk factors provides a crucial approach to the prevention of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Moderately elevated plasma total homocysteine (tHcy) is a strong modifiable risk factor for vascular dementia and Alzheimer's disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia is a leading global cause of morbidity and mortality. 2 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Science can help to target climate finance at better-quality adaptation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neighborhood deprivation was associated with poorer cognition (r = 0.36, p < 0.001), greater prevalence of modifiable risk factors (r = 0.36, p < 0.001), and greater SVD burden (β = 0.18, p = 0.008). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over the past decade, Latin America and the Caribbean (LAC) have made progress in implementing the Sendai Framework for Disaster Risk Reduction 2015–2030 (SFDRR). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over a median follow-up of 13 years, 5,304 participants developed dementia. 4 key findings →
Participants: 151,832 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The exposome factors, such as diet, lifestyle, microbiome, chemical exposures and social exposome, shapes human health beyond genetic influences, but the mechanisms remain only partially understood. 1 key finding →
Participants: 449 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →